
Dr. Joshua Richter and Dr. Surbhi Sidana discuss the evolving role of belantamab mafodotin in relapsed/refractory multiple myeloma following its reapproval based on the DREAMM-7 trial and additional evidence from DREAMM-8. Dr. Sidana reviews the efficacy of belantamab-based combinations and considers how they compare with BCMA-directed CAR T-cell therapies and bispecific antibodies.








